To maintain its NYSE listing, Verso has until February 14, 2014, which is six months from the date of the NYSE notice, to bring the closing share price and the average closing share price of its common stock back above $1.00. Verso has notified the NYSE that it intends to cure the share price deficiency. During the cure period, Verso's common stock will continue to be traded on the NYSE, subject to Verso's compliance with other NYSE continued listing requirements.
Separately, and as previously disclosed, Verso has appealed the NYSE staff's determination to delist its common stock due to the company's failure to satisfy the NYSE's continued listing standard requiring that it have an average market capitalization of at least $75 million over a consecutive 30 trading-day period. The review committee of the NYSE's board of directors currently is scheduled to hear Verso's appeal on September 10.
TAPPI
http://www.tappi.org/